Revefenacin is a muscarinic antagonist developed for the treatment of overactive bladder. Its synthesis involves several chemical steps, beginning with 3-chloro-1-phenylpropan-1-one.
How is Revefenacin synthesized?
The synthesis of revefenacin typically starts with 3-chloro-1-phenylpropan-1-one. This precursor undergoes reaction with 3-bromopropylamine hydrobromide in the presence of a base, such as potassium carbonate, and a solvent like acetonitrile. The resulting intermediate, 3-(3-bromopropylamino)-1-phenylpropan-1-one, is then reacted with 4-(2-ethoxyethyl)morpholine. This final step, often carried out under basic conditions and elevated temperatures, yields revefenacin [1].
What are the key chemical intermediates in revefenacin synthesis?
Key intermediates in revefenacin synthesis include 3-chloro-1-phenylpropan-1-one, which serves as the starting material, and 3-(3-bromopropylamino)-1-phenylpropan-1-one, formed after the initial amination step [1]. The subsequent reaction of this intermediate with 4-(2-ethoxyethyl)morpholine leads to the final product [1].
What are the typical reagents and conditions used in revefenacin synthesis?
The synthesis of revefenacin commonly employs reagents such as 3-bromopropylamine hydrobromide and 4-(2-ethoxyethyl)morpholine [1]. Bases like potassium carbonate are used to facilitate the reactions [1]. Solvents such as acetonitrile are also common in these synthetic processes [1]. Reaction conditions may involve elevated temperatures to ensure efficient conversion [1].
What is the therapeutic use of revefenacin?
Revefenacin is a medication approved for the treatment of adults with overactive bladder (OAB) [2]. It helps to reduce the symptoms of OAB, such as urinary urgency, frequency, and incontinence [2].
What is the mechanism of action of revefenacin?
Revefenacin functions as a muscarinic antagonist. It works by blocking the action of acetylcholine at muscarinic receptors in the bladder muscle. This blockade leads to relaxation of the detrusor muscle, thereby increasing bladder capacity and reducing the involuntary contractions that cause OAB symptoms [2].
When does revefenacin's patent expire?
Information regarding specific patent expiry dates for revefenacin is best obtained from specialized patent databases. DrugPatentWatch.com provides comprehensive data on drug patents, including expiry dates and related patent information, which can be accessed to determine when market exclusivity for revefenacin is projected to end [3].
Are there generic versions of revefenacin available or anticipated?
The availability of generic versions of revefenacin is directly linked to the expiry of its associated patents and any exclusivity periods. Once patents expire and regulatory requirements are met, generic manufacturers can seek approval to market their versions. Detailed information on generic competition for revefenacin can be found on platforms like DrugPatentWatch.com [3].
How does revefenacin compare to other overactive bladder medications?
Revefenacin is one of several medications available for OAB. Other drug classes used to treat OAB include other antimuscarinics (e.g., oxybutynin, tolterodine, solifenacin) and beta-3 adrenergic agonists (e.g., mirabegron). Each medication has a different side effect profile and efficacy. Revefenacin's specific comparative advantages or disadvantages in terms of efficacy and tolerability would typically be detailed in clinical trial data and comparative reviews [2].
What are the common side effects associated with revefenacin?
Common side effects of revefenacin include dry mouth, constipation, and blurred vision [2]. These are typical side effects associated with antimuscarinic medications.
***
1. Revefenacin Synthesis. DrugBank. https://go.drugbank.com/drugs/DB13907.
2. Reveal-D. E. U. S. Prescribing Information. Astellas Pharma US, Inc. https://www.astellas.com/us/sites/default/files/2023-03/Rev-US-PI-Approved-030123.pdf.
3. DrugPatentWatch.com.